Mapi appoints Dr. Margaret (Meg) Richards to Vice President, Data Analytics and Epidemiology
BOSTON, Feb. 6, 2017 /PRNewswire/ -- Mapi, a global leader in Real-World Evidence, Real World Strategy and Analytics, Epidemiology and Patient-Centered Research solutions, strengthens its Epidemiology team with the appointment of Dr. Margaret (Meg) Richards as a Vice President, Data Analytics and Epidemiology joining the Real World Strategy & Analytics team.
Dr. Richards is an accomplished epidemiologist with expertise spanning senior leadership, research and teaching, and project design and execution. She has a wealth of experience in epidemiology, drug safety, health services and health outcomes research, including extensive experience in survey research methodology and analysis.
"Meg brings a great deal of expertise within the CRO industry as an Executive Director of Epidemiology and Health Outcomes leading a global department focused on non-interventional late phase studies," commented Dr. Terri Madison, Sr. Vice President and Head, Real World Strategy and Analytics. "Meg also has several years of experience with large biopharmaceutical companies including Sanofi-Genzyme and Abbott."
Dr. Richards' experience includes working in the government sector as Deputy Director (Epidemiology) in the Illinois Department of Public Health, the non-profit sector as a Senior Scientist working on Medicare quality improvement and program evaluation, and in the biopharmaceutical industry focused on drug safety and outcomes research.
She is also actively engaged in several industry professional associations, including the Drug Information Association where she has served on the annual meeting program committee since 2010. Dr. Richards received her MPH and PhD (Epidemiology) at the University of Illinois at Chicago. She also completed a postdoctoral program with the US Centers for Disease Control & Prevention's Epidemic Intelligence Service.
To learn more about Mapi's capabilities visit mapigroup.com.
About Mapi: Patients are at the heart of our research
Mapi Group has over 40 years of experience supporting Life-Science companies in developing and implementing strategies for commercializing novel treatments through Strategic Regulatory Services, Pharmacovigilance, Market Access, Language Services, and gathering Real-World Evidence on Pharmaceuticals, Biologicals, and Medical Devices. Mapi Group is the premier provider of Health Research and Commercialization services to Life-Science companies enabling Market Authorization, Market Access and Market Adoption of novel therapeutics. Visit mapigroup.com for more information.
Press contact: [email protected]
SOURCE Mapi
Share this article